Connexin 43 and tumors

doi:10.3760/cma.j.issn.1673-422X.2018.01.007

Abstract

Abstract: Cell gap junction is a special protein channel. Gap junctionmediated exchange of information between cells is crucial for cell growth, differentiation and tissue homeostasis. Connexin 43 (Cx43) is one of the members of the gap junction protein family. In recent years, researches show that abnormal Cx43 gene expression leads to the cell gap junctional communication dysfunction, which is closely related to the occurrence, metastasis and prognosis of a variety of tumors. Cx43 is expected to become a new target for clinical diagnosis and treatment of tumors.

Key words: Connexin 43, Neoplasms, Cell communication

Wen Xiaorong*, Mo Hongmei, Guo Tao, Ding Mengting. Connexin 43 and tumors[J]. Journal of International Oncology, 2018, 45(1): 32-.

References

［1］ Grek CL, Rhett JM, Ghatnekar GS. Cardiac to cancer: connecting connexins to clinical opportunity［J］. FEBS Lett, 2014, 588(8): 13491364. DOI: 10.1016/j.febslet.2014.02.047. ［2］ Rhett JM, Fann SA, Yost MJ. Purinergic signaling in early inflammatory events of the foreign body response: modulating extracellular ATP as an enabling technology for engineered implants and tissues［J］. Tissue Eng Part B Rev, 2014, 20(5): 392402. DOI: 10.1089/ten.TEB.2013.0554. ［3］ Jin Z, Xu S, Yu H, et al. miR125b inhibits Connexin43 and promotes glioma growth［J］. Cell Mol Neurobiol, 2013, 33(8): 11431148. DOI: 10.1007/s1057101399801. ［4］ Ableser MJ, Penuela S, Lee J, et al. Connexin43 reduces melanoma growth within a keratinocyte microenvironment and during tumorigenesis in vivo［J］. J Biol Chem, 2014, 289(3): 15921603. DOI: 10.1074/jbc.M113.507228. ［5］ Chen R, Luan Y, Liu Z, et al. AR pathway is involved in the regulation of CX43 in prostate cancer［J］. Biomed Res Int, 2015, 2015: 514234. DOI: 10.1155/2015/514234. ［6］ Macdonald AI, Sun P, HernandezLopez H, et al. A functional interaction between the MAGUK protein hDIg and the gap junction protein connexin 43 in cervical tumour cells［J］. Biochem J, 2012, 446(1): 921. DOI: 10.1042/BJ20111144. ［7］ Sun P, Dong L, MacDonald AI, et al. HPV16 E6 controls the gap junction protein Cx43 in cervical tumour cells［J］. Viruses, 2015, 7(10): 52435256. DOI: 10.3390/v7102871. ［8］ Sulkowska U, Wincewicz A, KanczugaKoda L, et al. Eventual proapoptotic or antiapoptotic impact of aberrantly expressed Cx43 and Cx26 can depend on ERalpha overexpression in human endometrioid adenocarcinoma［J］. Gynecol Endocrinol, 2015, 31(8): 604608. DOI: 10.3109/09513590.2015.1017811. ［9］ Matharu G, Tucker O, Alderson D. Systematic review of intraperitoneal chemotherapy for gastric cancer［J］. Br J Surg, 2011, 98(9): 12251235. DOI: 10.1002/bjs.7586. ［10］ Tang B, Peng ZH, Yu PW, et al. Aberrant expression of Cx43 is associated with the peritoneal metastasis of gastric cancer and Cx43mediated gap junction enhances gastric cancer cell diapedesis from peritoneal mesothelium［J］. PLoS One, 2013, 8(9): e74527. DOI: 10.1371/journal.pone.0074527. ［11］ Fu Y, Shao ZM, He QZ, et al. HsamiRV206 represses the proliferation and invasion of breast cancer cells by targeting Cx43［J］. Eur Rev Med Pharmacol Sci, 2015, 19(11): 20912104. ［12］ Lamiche C, Clarhaut J, Strale PO, et al. The gap junction protein Cx43 is involved in the bonetargeted metastatic behaviour of human prostate cancer cells［J］. Clin Exp Metastasis, 2012, 29(2): 111122. DOI: 10.1007/s1058501194344. ［13］ Zhang A, Hitomi M, BarShain N, et al. Connexin 43 expression is associated with increased malignancy in prostate cancer cell lines and functions to promote migration［J］. Oncotarget, 2015, 6(13): 1164011651. DOI: 10.18632/oncotarget.3449. ［14］ Qiu X, Cheng JC, Zhao J, et al. Transforming growth factorβ stimulates human ovarian cancer cell migration by upregulating connexin43 expression via Smad2/3 signaling［J］. Cell Signal, 2015, 27(10): 19561962. DOI: 10.1016/j.cellsig.2015.07.010. ［15］ Liu X, Cao K, Xu C, et al. GATA3 augmentation downregulates Connexin43 in helicobacter pylori associated gastric carcinogenesis［J］. Cancer Biol Ther, 2015, 16(6): 987996. DOI: 10.1080/15384047.2015.1030552. ［16］ Ming J, Zhou Y, Du J, et al. miR381 suppresses C/EBPαdependent Cx43 expression in breast cancer cells［J］. Biosci Rep, 2015, 35(6). pii: e00266. DOI: 10.1042/BSR20150167. ［17］ Brockmeyer P, Hemmerlein B, Jung K, et al. Connexin subtype expression during oral carcinogenesis: a pilot study in patients with oral squamous cell carcinoma［J］. Mol Clin Oncol, 2016, 4(2): 298302. DOI: 10.3892/mco.2015.685. ［18］ Brockmeyer P, Jung K, Perske C, et al. Membrane connexin 43 acts as an independent prognostic marker in oral squamous cell carcinoma［J］. Int J Oncol, 2014, 45(1): 273281. DOI: 10.3892/ijo.2014.2394. ［19］ Ismail R, Rashid R, Andrabi K, et al. Pathological implications of Cx43 downregulation in human colon cancer［J］. Asian Pac J Cancer Prev, 2014, 15(7): 29872991. ［20］曹建, 孙萍. Ⅱ期结肠癌的辅助化学治疗［J］. 国际肿瘤学杂志, 2013, 40(6): 463465. DOI: 10.3760/cma. j.issn.1673422X.2013.06.020. ［21］ Wang J, Dai Y, Huang Y, et al. Alltrans retinoic acid restores gap junctional intercellular communication between oral cancer cells with upregulation of Cx32 and Cx43 expressions in vitro［J］. Med Oral Patol Oral Cir Bucal, 2013, 18(4): e569e577. ［22］ Forster T, Rausch V, Zhang Y, et al. Sulforaphane counteracts aggressiveness of pancreatic cancer driven by dysregulated Cx43mediated gap junctional intercellular communication［J］. Oncotarget, 2014, 5(6): 16211634. DOI: 10.18632/oncotarget.1764. ［23］ Grek CL, Rhett JM, Bruce JS, et al. Targeting connexin 43 with αconnexin carboxylterminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1［J］. BMC Cancer, 2015, 15: 296. DOI: 10.1186/s1288501512296. ［24］ Ghosh S, Kumar A, Chandna S. Connexin43 downregulation in G2/M phase enriched tumour cells causes extensive lowdose hyperradiosensitivity (HRS) associated with mitochondrial apoptotic events［J］. Cancer Lett, 2015, 363(1): 4659. DOI: 10.1016/j.canlet.2015.03.046.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.